

FILE 'HOME' ENTERED AT 07:52:47 ON 02 MAY 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:52:58 ON 02 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

DICTIONARY FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\VR1.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam sam

SAMPLE SEARCH INITIATED 07:53:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA FAM SAM L1

=> s l1 fam full

FULL SEARCH INITIATED 07:53:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01


L3 1 SEA FAM FUL L1

=> d scan

L3 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4-Quinazolinamine, 7-[3-(trifluoromethyl)-2-pyridinyl]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI)

MF C20 H11 F6 N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

68.60

68.81

FILE 'CAPLUS' ENTERED AT 07:54:52 ON 02 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2007 VOL 146 ISS 19
FILE LAST UPDATED: 1 May 2007 (20070501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 2 L3

=> d ti au abs so py 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Combination therapy comprising a heteroarylamine VR1 antagonist and a narcotic analgesic for the treatment of pain with reduced addictive side effects

IN Herzberg, Uri; Cortright, Daniel; Hurtt, Mark M.; Krause, James E.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compns. comprising a nontoxic vanilloid receptor 1 (VR1) antagonist, optionally in combination with an addictive therapeutic agent, for the treatment of pain. Compns. and methods are further provided for inhibiting the development of tolerance to addictive therapeutic agents (especially narcotic analgesics) in patients treated with such agents, for minimizing adverse effects (e.g., dependence) resulting from treatment with such addictive agents, and for enhancing pain relief resulting from narcotic analgesic administration. Patients may be treated with a VR1 antagonist before, during, or after administration of the addictive therapeutic agent to prevent, decrease the severity of, delay, or treat tolerance and/or other adverse effects of the addictive agent in the patient. Examples include synthetic methods and limited data for the preparation of representation heteroarylamine VR1 antagonists, as well as capsaicin receptor binding assays and numerous pain model assays. For instance, coupling of 7-bromo-4-chloroquinazoline with 2-amino-5-trifluoromethylpyridine, followed by addition of 3-fluoro-2-tributylstannylpyridine provided I. In a bioassay testing the inhibition of tolerance to morphine, rats receiving morphine plus II exhibited statistically significantly higher withdrawal thresholds than any other treatment group, indicating that the VR1 antagonist prevents tolerance to repeated morphine dosing.


SO PCT Int. Appl., 182 pp.

CODEN: PIXXD2

PY 2004

2004
2004
2004
2005
2006

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin
receptor antagonists for relieving pain
IN Bakthavatchatam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.;
Caldwell, Timothy M.; De Lombaert, Stephane
GI



AB Substituted quinazolin-4-ylamine analogs (shown as I; variables defined below; e.g. (4-trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine) are provided. Such compds. are ligands that may be used to modulate VR1 capsaicin receptor activity in vivo or in vitro (no data), and are particularly useful in the treatment of conditions associated with pathol. receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. For I; V, X, W, Y and Z are each independently N or CR1, with the proviso that at least one of V and X is N; U is N or CR2, with the proviso that if V and X are N, then U is CR2; R1 = H, halogen, hydroxy, amino, C1-C8 alkyl, haloC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkoxy and mono- and di(C1-C8alkyl)amino. R2 = (i) H, halogen, cyano, or -COOH; (ii) C1-C8alkanoyl, C2-C8alkanone, or C1-C8carbamate, each of which is (un)substituted with 1-9 substituents = Rb, or (iii) -Rc-M-A-Ry, wherein: Rc is C0-C3alkyl; M is a bond, N(Rz), O, S, SO2, (C:O)pN(Rz), N(Rz)(C:O)p, SO2N(Rz), or N(Rz)SO2, wherein p is 0 or 1; A is a bond or C1-C8alkyl, (un)substituted with 1-3 Rb. Ry and Rz, if present, are: (a) independently H, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C6-C10arylC1-C8alkyl, C2-C8alkyl ether, C1-C8alkoxy, a 4- to 10-membered carbocycle or heterocycle, or joined to R1 to form a 4- to 10-membered carbocycle or heterocycle, wherein each Ry and Rz = (un)substituted with 1-9 Rb; or (b) joined to form a 4- to 10-membered carbocycle or heterocycle that is (un)substituted with 1-9 Rb; Ar2 is a 5- to 7-membered aromatic heterocycle, (un)substituted with 1-3 LRa. Ar1 is a 5- to 10-membered aromatic carbocycle or heterocycle, (un)substituted with 1-3 LRa; L = bond, -O-, -C(O)-, -OC(O)-, -C(O)O-, -O-C(O)O-, -S(O)m-, -NRx-, -C(O)NHRx-, -NHRxC(O)-, -NRxS(O)m-, -S(O)mNRx- and -N[S(O)mRx]S(O)m-; wherein m = 0, 1 and 2; and Rx = H and C1-C8alkyl; Ra = (i) H, halogen, cyano and nitro; and (ii) C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C2-C8alkyl ether, 3- to 10-membered heterocycles, mono- and di(C1-C8alkyl)amino and (3- to 10-membered heterocycle)C1-C6 alkyl, each of which is (un)substituted with 1-9 Rb. Rb = hydroxy, halogen, amino, aminocarbonyl, amido, cyano, nitro, C1-C8alkyl, C1-C8alkoxy, C1-C8alkylthio, C1-C8alkyl ether, hydroxyC1-C8alkyl, haloC1-C8alkyl, Ph, phenyl(C1-C8alkyl), mono and di(C1-C6 alkyl)amino, (SO2)C1-C8alkyl, 5- to 7-membered heterocycle and (5- to 7-membered heterocycle)(C1-C8alkyl). Although the methods of preparation are not claimed, many example preps. and characterization data for >500 examples of I are included.

SO PCT Int. Appl., 294 pp.
CODEN: PIXXD2

PY 2003
2003
2003
2004
2004
2005
2005
2005
2004
2006
2005
2005
2004
2006

=>

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	202	vr1 adj antagonist	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/05/02 07:24
S2	16608	morphine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/05/02 07:25
S3	46	S1 and S2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/05/02 07:37
S4	256	vr1 adj antagonist or vr1 adj modulator or capsaicin adj antagonist	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/05/02 07:37
S5	49	S2 and S4	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2007/05/02 07:59
S6	2	bakthavatchatam	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2007/05/02 08:42
S7	1	wo "2003074520"	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2007/05/02 08:52
S8	70	"5574052"	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2007/05/02 08:52